Author/Authors :
Atsuya Takami، نويسنده , , Masayuki Iwakubo، نويسنده , , Yuji Okada، نويسنده , , Takehisa Kawata، نويسنده , , Hideharu Odai، نويسنده , , Nobuaki Takahashi، نويسنده , , Kazutoshi Shindo، نويسنده , , Kaname Kimura، نويسنده , , Yoshimichi Tagami، نويسنده , , Mika Miyake، نويسنده , , Kayoko Fukushima، نويسنده , , Masaki Inagaki، نويسنده , , Mutsuki Amano، نويسنده , , Kozo Kaibuchi and Toshio Hakoshima، نويسنده , , Hiroshi Iijima، نويسنده ,
Abstract :
Several structurally unrelated scaffolds of the Rho kinase inhibitor were designed using pharmacophore information obtained from the results of a high-throughput screening and structural information from a homology model of Rho kinase. A docking simulation using the ligand-binding pocket of the Rho kinase model helped to comprehensively understand and to predict the structure–activity relationship of the inhibitors. This understanding was useful for developing new Rho kinase inhibitors of higher potency and selectivity. We identified several potent platforms for developing the Rho kinase inhibitors, namely, pyridine, 1H-indazole, isoquinoline, and phthalimide.
Keywords :
Rho kinase , Structure–activity relationship , Inhibitor , structure-based drug design